NIH COVID-19 Impact on Extramural Institutions Survey Supplemental Frequency Tables

May 2021

Prepared for the NIH Chief Officer for Scientific Workforce Diversity

Prepared by Deloitte

NIH COVID-19 Impact on Extramural Institutions Survey

Supplemental Frequency Tables

This document summarizes the frequencies for all questions in the 2020 National Institutes of Health (NIH) COVID-19 Impact on Extramural Institutions Survey. The survey was fielded to 706 research leaders (VP of Research or equivalent) at the top 1,000 NIH-funded institutions between October 7 and November 6, 2020, and received a total of 224 responses for a 32% response rate.

During the survey, respondents were asked about the status of research operations at their institutions, financial concerns their institutions face, impacts on the research workforce and research productivity, as well as mitigation plans their institutions have implemented to support researchers and facility reopening. When possible, survey measures were based on validated survey items or scales. However, some measures were modified or revised based on the target population and the survey goals.

Prior to fielding, selected questions from the NIH COVID-19 Impact on Extramural Institutions Survey underwent cognitive testing with 9 research leaders to test understanding of survey items and identify areas for improvement. Pilot testing of the questionnaire was then conducted with 12 additional research leaders. Survey items were revised based on cognitive testing and pilot testing feedback prior to fielding the survey with all research leaders beginning October 2020.

How to Use this Document

Following the conclusion of survey fielding, a series of comprehensive reports were created based on the analyses of survey results. To complement these reports, the Supplemental Frequency Tables within this document include the number (i.e., frequency) of survey respondents selecting each response option. Respondents were given the option to skip any question on the survey. The purpose of the supplemental tables is to provide additional context to the survey findings and support the NIH in potential future administrations of the survey instrument.

All survey questions are presented in this document in the order and format they were administered to respondents when the survey was fielded in 2020.

Table Format:

[question #] [survey question text]		
[frequency]	[response option]	
[frequency]	[response option]	

Q1. Which of the following best describes your institution?

	Doctorate-granting university with a professional school (e.g., medical, pharmacy,
117	veterinary, dental)
	Doctorate-granting university without a professional school (e.g., medical, pharmacy,
38	veterinary, dental)
<10	Master's college/university
<10	Baccalaureate college/university
<10	Associate's college/community college
42	Independent research institute or organization (please specify)
<10	Special focus institution (e.g., technology, arts-related, cancer center) (please specify)
12	Other (please specify)
2	No response

Q1a. Which state/territory is your institution located in?

<10	Alabama
<10	Arizona
<10	Arkansas
<10	California
<10	Colorado
<10	Connecticut
<10	Delaware
<10	Florida
<10	Georgia
<10	Hawaii
<10	Illinois
<10	Indiana
<10	Iowa
<10	Kansas
<10	Kentucky
<10	Louisiana
<10	Maine
<10	Maryland
20	Massachusetts
<10	Michigan
<10	Minnesota
<10	Missouri
<10	Montana
<10	Nebraska
<10	New Hampshire
<10	New Jersey
17	New York
<10	North Carolina
<10	North Dakota
10	Ohio
<10	Oklahoma
<10	Oregon

<10	Pennsylvania
<10	Rhode Island
<10	South Carolina
<10	South Dakota
<10	Tennessee
10	Texas
<10	Utah
<10	Vermont
<10	Virginia
<10	Washington
<10	West Virginia
<10	Wisconsin
<10	Guam
<10	Washington D.C.
11	No response
•	yed only if Q1 ≠ Independent research institute or organization
Q2. Does yo	our institution consider itself to be a Minority Serving Institution (MSI)?
40	Yes
137	No
Q3. Does yo	our institution consider itself to be one or more of the following? Please select all that
<10	Historically Black College or University (HBCU)
<10	Primarily Black Institution (PBI)
22	Hispanic-Serving Institution (HSI)
<10	Tribal College or University (TCU)
<10	Native American Non-Tribal Institution (NANTI)
<10	Alaskan Native or Native Hawaiian-Serving Institution (ANNHI)
10	Asian American and Native American Pacific Islander-Serving Institution (AANAPISI)
<10	Other (please specify)
	title/role related to research oversight?
219	Yes
<10	No
1	No response
	ayed only if Q4 = No
	urvey is intended for those in roles that oversee research. Please indicate below if you
	to participate in the survey.
<10	I would like to participate in this survey
<10 <10	^ ^

Q5 is displa	Q5 is displayed only if Q4 = Yes	
Q5. What is	Q5. What is your title/role?	
12	Executive Vice President for Research	
75	Vice President for Research	
21	Vice Provost for Research	
<10	Vice Dean for Research	
16	Vice Chancellor for Research	
<10	Senior Associate Dean for Research	
<10	Associate Dean for Research	
<10	Associate Provost for Research	
10	Chief Scientific Officer	
<10	Chief Medical Officer	
<10	Center Director	
51	Other (please specify)	
5	No response	

Q6. Which NIH-related science areas are the largest recipients of NIH funding at your institution? Please select up to three choices.

142	Biological Sciences
20	Data Sciences
<10	Dentistry
<10	Education
29	Engineering/Technology
143	Health Sciences/Medicine
24	Interdisciplinary
10	Mathematical/Computational Sciences
<10	Nursing
16	Pharmacy
14	Physical Sciences
46	Public Health
53	Social and Behavioral Sciences
<10	Veterinary Medicine
14	Other (please specify)
3	No response

Q7. Thinking about the last 30 days, what has been the status of your institution concerning on-site researchers and research activities as a result of COVID-19?

64	Our institution has been open at full or close-to-full capacity to all on-site researchers and
	research activities
54	Our institution has been open at reduced capacity to all on-site researchers and research activities
45	Our institution has been open at full or close-to-full capacity for some researchers and reduced capacity for others
57	Our institution has been open at reduced capacity for some on-site researchers and research activities, with other research continuing to take place remotely/off-site
	Our institution has been completely closed to on-site researchers/research activities, but
<10	research continues to take place remotely/off-site
2	No response

Q8 is displayed only if Q7 \neq Our institution has been completely closed

Q8. Has your institution implemented any safety measures to protect the health of researchers and research support staff?

	rr
221	Yes
<10	No

Q9. Which of the following factors resulting from COVID-19 have had the *most negative impact* on your institution's research function? Please select up to three choices. RANDOM ROTATE

<10	Inadequate communication with leadership
50	Increased virtual meetings
49	Shift from in-person to online classrooms
43	Increased administrative responsibilities
<10	Faculty/staff layoffs
26	Furloughs due to institutional budget cuts
71	Institutional hiring freezes
45	Concerns about enrollment numbers
45	Visa considerations
<10	Individuals testing positive for COVID-19
<10	Fatalities due to COVID-19
19	Insufficient access to personal protective equipment (PPE) (e.g., masks, industrial-grade
	sanitizing products, hand sanitizers, or other products)
32	
	tests, resources to conduct tests)
138	Reduced access to on-site laboratories
27	Increased faculty teaching requirements
40	Other (please specify)
<10	None of the above EXCLUSIVE
2	No response

Q10. How concerned are you about the impact of COVID-19 on the financial status of your institution?

67	Extremely concerned
80	Very concerned
58	Moderately concerned
17	Slightly concerned
<10	Not at all concerned
2	No response

Q11. Based on what you know now, how likely is it that the financial repercussions of COVID-19 will jeopardize your institution's ability to maintain its research function?

<u> </u>	· ·
20	Extremely likely
70	Likely
51	Neutral
57	Unlikely
24	Extremely unlikely
2	No response

Q12. Thinking about the institution where you oversee research, which, if any, of the following factors has had a *substantial impact* on your institution as a result of COVID-19? Please select all that apply. RANDOM ROTATE

116	Unexpected costs associated with increased spending on technology to facilitate remote
	work
75	Decrease in philanthropic revenue sources (e.g., non-governmental revenue from
	fundraising, private foundation grants)
32	Loss of endowment funding or capital market programs
54	Loss of revenue from athletics
80	Loss of revenue from activities (e.g., camps, summer programs, daycare)
105	Loss of housing and dining revenue with students leaving campus earlier than planned
45	Unexpected costs associated with staff and students moving off campus
93	Reduction in tuition revenue from students
155	Increased expenses involved with ensuring safety of staff and students (e.g., cleaning,
	testing, extra housing space for quarantining)
75	Loss of state funding
28	Other (please specify)
<10	None of the above EXCLUSIVE
6	No response

Q13. Which, if any, of the below have happened at your institution due to COVID-19? Please select all that apply. RANDOM ROTATE

	· ·
79	Salary cuts
168	Budget cuts
87	Furloughs
61	Terminations
77	Reduced hours
55	Loss of grants, endowments, or sponsorships
129	Loss of tuition and revenue
163	Freezes in hiring
22	Revocation of approved job offers
202	Reductions in travel
82	Cancellation of programs
65	Offerings of early retirement
64	Loss of daycare
90	Delay in promotion timelines
18	Other (please specify)
<10	None of the above EXCLUSIVE
3	No response

How much of a priority do you consider the following practices to be in restoring research operations?

Q14. Maintaining a healthy environment through the cleaning and disinfecting of facilities

<10	Not a priority
<10	Low priority
17	Medium priority
48	High priority
153	Essential
4	No response

Q15. Implementing a COVID-19 testing program to protect the research workforce

<10	Not a priority
14	Low priority
42	Medium priority
65	High priority
92	Essential
6	No response

Q16. Developing and implementing phased plans to return to the workplace safely

<10	Not a priority
<10	Low priority
15	Medium priority
59	High priority
137	Essential
6	No response

<10	Not a priority
<10	Low priority
13	Medium priority
65	High priority
134	Essential
5	No response
Preve	nting workforce layoffs and furloughs
<10	Not a priority
<10	Low priority
44	
113	High priority
48	Essential
7	No response
Prom	oting research that can be conducted remotely
10	Not a priority
22	Low priority
66	Medium priority
77	High priority
43	Essential
6	No response
Addr	essing the specific needs of research that can only be done on-site
	Not a priority
<10	
<10 <10	Low priority
<10	Low priority Medium priority High priority
<10 16	Low priority Medium priority
<10 16 77	Low priority Medium priority High priority
<10 16 77 120	Low priority Medium priority High priority Essential
<10 16 77 120 4	Low priority Medium priority High priority Essential
<10 16 77 120 4	Low priority Medium priority High priority Essential No response
<10 16 77 120 4	Low priority Medium priority High priority Essential No response lying with operational and reporting requirements of grant-funding
<10 16 77 120 4 . Comp	Low priority Medium priority High priority Essential No response lying with operational and reporting requirements of grant-funding Not a priority
<10 16 77 120 4 Comp <10 <10	Low priority Medium priority High priority Essential No response lying with operational and reporting requirements of grant-funding Not a priority Low priority
<10 16 77 120 4 Comp <10 <10 27	Low priority Medium priority High priority Essential No response lying with operational and reporting requirements of grant-funding Not a priority Low priority Medium priority

Q22. Since the transition to maximized remote work at your institution, how much has COVID-19 impacted overall research productivity, including research activities and outcomes?

<10	No impact
20	Minor impact
116	Moderate impact
69	Major impact
15	Don't know yet
2	No response

In your opinion, what has been the impact of COVID-19 on the following research activities at your institution?

Q23. Publishing journal articles, books, etc.

<10	Strong negative impact
43	Negative impact
90	Neutral
57	Positive impact
12	Strong positive impact
<10	N/A
9	No response

Q24. Research site/laboratory access for research deemed "noncritical" or "nonessential"

65	Strong negative impact
98	Negative impact
41	Neutral
<10	Positive impact
<10	Strong positive impact
<10	N/A
8	No response

Q25. Research site/laboratory access for research deemed "critical" or "essential"

14	Strong negative impact
88	Negative impact
82	Neutral
19	Positive impact
<10	Strong positive impact
<10	N/A
8	No response

Q26. Grant application submissions

<10	Strong negative impact
33	Negative impact
81	Neutral
72	Positive impact
20	Strong positive impact
<10	N/A
9	No response

.4.0	s awarded to the institution
<10	Strong negative impact
31	Negative impact
120	Neutral
51	Positive impact
<10	Strong positive impact
<10	N/A
9	No response
Conti	nuation of human (IRB) reviews
<10	Strong negative impact
45	Negative impact
138	Neutral
<10	Positive impact
<10	Strong positive impact
11	N/A
10	No response
	•
	nuation of animal (IACUC) reviews
<10	Strong negative impact
35	Negative impact
152	Neutral
<10	Positive impact
<10	Strong positive impact
-10	Strong positive impact
13	N/A
13	N/A
13	N/A
13	N/A No response
13 9	N/A No response s to clinic/human research subjects
13 9 • Access 97	N/A No response s to clinic/human research subjects Strong negative impact Negative impact Neutral
13 9 • Access 97 82	N/A No response s to clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact
13 9 • Access 97 82 17	N/A No response s to clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact
13 9 • Access 97 82 17 <10	N/A No response s to clinic/human research subjects Strong negative impact Negative impact Neutral
13 9 • Access 97 82 17 <10 <10	N/A No response s to clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact
13 9 . Access 97 82 17 <10 <10 15	N/A No response sto clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact N/A No response
13 9 . Access 97 82 17 <10 <10 15	N/A No response s to clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact N/A No response
13 9 . Access 97 82 17 <10 <10 15	N/A No response sto clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact N/A No response
13 9 . Access 97 82 17 <10 <10 15 8	N/A No response s to clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact N/A No response
13 9 . Access 97 82 17 <10 <10 15 8	N/A No response sto clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact N/A No response sto experimental animals Strong negative impact
13 9 Access 97 82 17 <10 <10 15 8 Access 18 90	N/A No response sto clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact N/A No response sto experimental animals Strong negative impact Negative impact
13 9 Access 97 82 17 <10 <10 15 8 Access 18 90 91	N/A No response s to clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact N/A No response s to experimental animals Strong negative impact Negative impact Negative impact
13 9 Access 97 82 17 <10 <10 15 8 Access 18 90 91 <10	N/A No response Sto clinic/human research subjects Strong negative impact Negative impact Neutral Positive impact Strong positive impact N/A No response Sto experimental animals Strong negative impact Negative impact Negative impact Negative impact Negative impact Negative impact Neutral Positive impact

<10	Strong negative impact
<10	Negative impact
62	Neutral
51	Positive impact
17	Strong positive impact
78	N/A
9	No response
	per of support staff on-site
28	Strong negative impact
138	Negative impact
46	Neutral
<10	Positive impact
<10	Strong positive impact
<10	N/A
9 ce trans	No response itioning to remote work, how has the workload in the following research areas changed
9 ce trans	
9 ce trans l. Wet l	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot
9 ce trans . Wet l: 51 125	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some
9 ce trans l. Wet l	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot
9 ce trans 1. Wet 1: 51 125 11	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact
9 Exercises Solution S	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased some
9 See trans 51 125 11 11 <10	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased some Increased a lot
9 2e trans 3. Wet 1: 51 125 11 10 <10 13	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response
9 2e trans 51 125 11 11 <10 <10 13	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response
9 2e trans 51 125 11 11 <10 <10 13	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response ab research Decreased a lot
9 2e trans 3. Wet 1: 125 11 11 <10 <10 13 3. Dry 1a 86	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response ab research Decreased a lot Decreased some
9 ce trans 1. Wet 1: 125 11 11 <10 <10 13 86 61	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response ab research Decreased a lot Decreased some No impact
9 ce trans 1. Wet 1: 125 11 11 <10 <10 13 86 61 37	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased a lot Not sure No response Ab research Decreased a lot Decreased a lot Decreased some Increased a lot Increased some Increased some Increased some Increased some Increased some
9 ce trans 1. Wet 1: 125 11 11 <10 <10 13 86 61 37 <10	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased a lot Not sure No response Ab research Decreased a lot Decreased some No impact Increased a lot Increased some Increased some Increased some Increased a lot
9 ce trans 1. Wet 1: 125 11 11 <10 <10 13 86 61 37	No response itioning to remote work, how has the workload in the following research areas changed ab research (e.g., drug, chemical, or biological-related) Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response Ab research Decreased a lot Decreased some No impact Increased a lot Increased a lot Increased a lot Increased some Increased a lot Increased some Increased some Increased some Increased some Increased some

Q50. Chinical trials	
Decreased a lot	
Decreased some	
No impact	
Increased some	
Increased a lot	
Not sure	
No response	

. Other	clinical research (e.g., observational studies, cohort studies)
69	Decreased a lot
82	Decreased some
26	No impact
<10	Increased some
<10	Increased a lot
22	Not sure
13	No response
	rioral and social sciences research (e.g., psychology experiments)
74	Decreased a lot
76	Decreased some
19	No impact
<10	Increased some
<10	Increased a lot
29	Not sure
17	No response
	ng and submitting peer-reviewed articles for publication Decreased a lot
51	Decreased some
46	No impact
46 86	1
46 86 15	No impact Increased some Increased a lot
86	Increased some
86 15	Increased some Increased a lot
86 15 13 11 Writin	Increased some Increased a lot Not sure No response ng and submitting book manuscripts, monographs, or conference proceedings for
86 15 13 11 . Writin lication	Increased some Increased a lot Not sure No response ng and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot
86 15 13 11 . Writing <10 43	Increased a lot Not sure No response ng and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some
86 15 13 11 . Writin lication <10 43 53	Increased a lot Not sure No response In and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact
86 15 13 11 . Writin cation 43 53 73	Increased some Increased a lot Not sure No response and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some
86 15 13 11 . Writing 10 43 53 73	Increased some Increased a lot Not sure No response In and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot
86 15 13 11 . Writin lication <10 43 53 73 11 24	Increased a lot Not sure No response In and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot Not sure
86 15 13 11 . Writing constraints of the second sec	Increased some Increased a lot Not sure No response In and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response In grant proposals
86 15 13 11 . Writin clication 43 53 73 11 24 13	Increased some Increased a lot Not sure No response In g and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response In g grant proposals Decreased a lot
86 15 13 11 . Writinglication <10 43 53 73 11 24 13 . Writinglication	Increased a lot Not sure No response Ing and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response Ing grant proposals Decreased a lot Decreased some
86 15 13 11 . Writin 10 43 53 73 11 24 13 . Writin 10 33	Increased some Increased a lot Not sure No response Ing and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response Ing grant proposals Decreased a lot Decreased some No impact
86 15 13 11 . Writinglication <10 43 53 73 11 24 13 . Writinglication <10 33 56 92	Increased some Increased a lot Not sure No response Ing and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response Ing grant proposals Decreased a lot Decreased some Increased a lot Not sure No impact Increased a lot Decreased some Increased a lot Decreased some Increased some Increased some Increased some Increased some
86 15 13 11 Note that the second sec	Increased some Increased a lot Not sure No response Ing and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response Ing grant proposals Decreased a lot Decreased some Increased a lot Increased some Increased a lot Increased some Increased a lot
86 15 13 11 . Writinglication <10 43 53 73 11 24 13 . Writinglication <10 33 56 92	Increased some Increased a lot Not sure No response Ing and submitting book manuscripts, monographs, or conference proceedings for Decreased a lot Decreased some No impact Increased some Increased a lot Not sure No response Ing grant proposals Decreased a lot Decreased some Increased a lot Not sure No impact Increased a lot Decreased some Increased a lot Decreased some Increased some Increased some Increased some Increased some

Q42. Collec	Q42. Collecting data	
40	Decreased a lot	
110	Decreased some	
27	No impact	
21	Increased some	
<10	Increased a lot	
<10	Not sure	
10	No response	
0.42 A1		
Q43. Analy		
<10	Decreased a lot	
31	Decreased some	
65	No impact	
92	Increased some	
13	Increased a lot	
<10	Not sure	
12	No response	
Q44. Super	vising laboratory staff	
15		
106	Decreased some	
49	No impact	
18	Increased some	
12	Increased a lot	
12	Not sure	
12	No response	
0.45 D		
	nting research findings	
86		
86		
24	No impact	
10	Increased some	
<10	Increased a lot	
<10	Not sure	
11	No response	
Q46. Collal	borating with colleagues	
48	Decreased a lot	
102	Decreased some	
22	No impact	
22	Increased some	
<10	Increased a lot	
11	Not sure	
11	No response	

Q47. If applicable, do you believe that COVID-19 will negatively affect the ability to earn tenure at your current institution?

49	Yes, it will make it harder to achieve tenure
68	No, it will not make it harder to achieve tenure
63	Not sure
40	N/A
4	No response

Q48 is displayed only if Q47 = Yes

Q48. You mentioned that COVID-19 may affect the ability of faculty to earn tenure. Which of the following statements is closest to your view?

36	Accommodations are in place to account for lost research time
10	We have not yet put accommodations into place, but we are planning on doing so
<10	We have not and are not planning to put accommodations in place

Q49. If applicable, do you believe that COVID-19 will negatively affect the ability of researchers/faculty to earn promotions at your current institution?

61	Yes, it will make it harder to achieve promotions
74	No, it will not make it harder to achieve promotions
72	Not sure
10	N/A
7	No response

Q50. Are researchers at the institution you oversee engaged in research aimed at understanding, preventing, or treating COVID-19?

185	Yes
27	No
<10	Not sure
<10	N/A
6	No response

Q51. Are researchers at the institution you oversee contributing to the literature on public health policy related to COVID-19 (e.g., modeling and forecasting the impacts of public health interventions)?

159	Yes
44	No
12	Not sure
<10	N/A
8	No response

Q52. Over the last 30 days, which of the following specialized research resources have been *most negatively impacted* by COVID-19 within your institution? Please select all that apply. RANDOM ROTATE

74	Access to core facilities
98	Access to laboratories
159	Access to clinic/human research subjects (e.g., in a clinical setting, in a community)
45	Access to animal care facilities
55	Access to supplies/specimens (e.g., autoclave, thermocycler, DNA sequencing equipment, mass spectrometers, surgical instruments, tissue, blood, and live animals)
109	Access to team members/colleagues
13	Access to data
61	Access to mentors
<10	Other (please specify)
12	None of the above EXCLUSIVE
10	No response

Q53. Does your institution have a phased physical return plan for staff, faculty, and graduate students?

195	Yes
10	No
<10	Not sure
10	N/A
8	No response

Q54. Is COVID-19 testing available for staff, faculty members, and students (if applicable) at your institution?

96	Yes, anyone can get tested
72	Yes, but only people who are symptomatic or who have had contact with someone who has
	COVID-19 can get tested
29	No
14	Not yet, but in planning phase
<10	Not sure
8	No response

Q55. Are contact tracing, transmission modeling, and other monitoring measures being implemented at your institution?

179	Yes
27	No
10	In planning phase
8	No response

Q56. Is there an organizational plan for reporting COVID-19 cases and emerging cases?

201	Yes
<10	No
<10	In planning phase
10	No response

Q57. In which of the following areas, if any, is your institution currently offering any COVID-19-related flexibilities for faculty/staff? Please select all that apply.

210	Telework
141	Tenure-clock considerations
66	Teaching hours
136	Employment hours
<10	Other (please specify)
<10	None of the above EXCLUSIVE
9	No response

Q58. How effectively has your institution managed the logistical process of returning to physical workplaces?

141	Very effectively
67	Somewhat effectively
<10	Not very effectively
<10	Not effectively at all
10	No response

Q59. To what extent do you agree or disagree with the following statement? My institution has provided clear guidance about returning to the workplace.

113	Strongly agree
86	Agree
<10	Neither agree nor disagree
<10	Disagree
<10	Strongly disagree
9	No response

Q60. Of the following measures, please select those that your institution has established in response to the COVID-19 pandemic. Please select all that apply.

197	A COVID-19 response team (addressing communications, responses, and/or processes for
	return to the physical workplace)
194	
	classrooms, and labs
97	Procedures for people with disabilities to safely return to the physical workplace
139	Procedures for people with a higher risk for severe illness from COVID-19 to safely return
	to the physical workplace
161	Policies and procedures to conduct clinical and non-clinical in-person research involving
	human subjects
181	Reconfigurations (or assignments) of physical space to research groups to promote social
	distancing
178	Policies and procedures in place for employees who do not feel comfortable with returning
	to the physical workplace
<10	Other (please specify)
<10	None of the above EXCLUSIVE
11	No response
· · · · · · · · · · · · · · · · · · ·	

How difficult will the following measures be to implement as the institution reopens?

O61.	Phy	vsical	dista	ncing
VUI.	1 11 1	, sicai	uista	11(1112

13	Very difficult
51	Difficult
116	Somewhat difficult
27	Not difficult at all
<10	N/A
14	No response

Q62. PPE and hand sanitizing provisions

<10	Very difficult
18	Difficult
63	Somewhat difficult
124	Not difficult at all
<10	N/A
15	No response

Q63. Contact tracing and tracking

	8
<10	Very difficult
48	Difficult
105	Somewhat difficult
41	Not difficult at all
<10	N/A
14	No response

Q64. Communal dining restrictions

24	Very difficult
60	Difficult
81	Somewhat difficult
28	Not difficult at all
17	N/A
14	No response

Q65. Campus and public transportation limitations

18	Very difficult
51	Difficult
84	Somewhat difficult
24	Not difficult at all
32	N/A
15	No response

Q66. Safe dormitory facilities and occupancy

20	Very difficult
55	Difficult
67	Somewhat difficult
<10	Not difficult at all
61	N/A
16	No response

Q67. Custodial services and sanitizing of classrooms and laboratory spaces

<10	Very difficult
38	Difficult
93	Somewhat difficult
63	Not difficult at all
10	N/A
16	No response

Q68. Health care providers available for staff

11	Very difficult
33	Difficult
57	Somewhat difficult
75	Not difficult at all
31	N/A
17	No response

Q69. Some members of your faculty and staff may have household and caretaking responsibilities due to COVID-19. Caretaking responsibilities include childcare, schooling, elder person care, disabled care, and/or care for ill household and/or family members. Is the institution providing/expanding facilities for childcare/family care services to accommodate the care needs of research staff?

45	Yes
116	No
23	In planning phase
28	Don't know
12	No response

The NIH has created a webpage "COVID-19: Information for NIH Applicants and Recipients of NIH Funding" to share how NIH's applicant and recipient community may continue its research.

Q70. Are you aware of this NIH webpage?

164	Yes
46	No
<10	Unsure
11	No response

\cap'	71	ic	dien	aved	only	, if (270	= Yes
v	/ I	18	aisb.	laveu	OHIV	/ II	ノノリ	- res

Q71. How helpful have you found the webpage "COVID-19: Information for NIH Applicants and Recipients of NIH Funding" in addressing your questions and concerns?

54	Very helpful
85	Somewhat helpful
18	Neither helpful nor unhelpful
<10	Barely helpful
<10	Not helpful at all

Q72. Please share with us any thoughts you may have around the impact of recent social unrest on research at your institution.

OPEN END

119	Total responses
105	No response

Q73. Please provide any additional feedback that you believe will be helpful to the NIH, including suggestions on how the NIH can support your institution during this period.

OPEN END

95	Total responses
129	No response

Q74. What is your age?

<10	18-24
<10	25-34
<10	35-44
55	45-54
87	55-64
46	65-74
<10	75 or older
10	Prefer not to answer
14	No response

Q75. What is your gender identity?

116	Man
78	Woman
<10	Transgender man
<10	Transgender woman
<10	Genderqueer or gender non-conforming
<10	Questioning
<10	Something else
14	Prefer not to answer
14	No response

	of the following do you consider yourself to be?
173	Heterosexual or straight
<10	Lesbian, Gay, or Homosexual
<10	Bisexual
<10	Asexual
<10	Questioning
<10	Something else
25	Prefer not to answer
16	No response
	ou of Hispanic, Latino, or Spanish origin?
<10	Yes
185	No De Contraction de la Contra
16	
16	No response
	<u> </u>
	which race do you most identify? Please select all that apply.
Q78. With v	which race do you most identify? Please select all that apply.
	which race do you most identify? Please select all that apply. White Black or African American
165	which race do you most identify? Please select all that apply. White
165 <10	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native Asian
165 <10 <10	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native
165 <10 <10 12	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native Asian
165 <10 <10 12 <10	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native Asian Native Hawaiian or Pacific Islander
165 <10 <10 12 <10 <10 10	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native Asian Native Hawaiian or Pacific Islander Other
165 <10 <10 12 <10 <10 11 12 <10 11 19 16	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native Asian Native Hawaiian or Pacific Islander Other Prefer not to answer
165 <10 <10 12 <10 <10 11 12 <10 11 19 16	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native Asian Native Hawaiian or Pacific Islander Other Prefer not to answer No response u have a disability?
165 <10 <10 12 <10 <10 <10 19 16 Q79. Do yo	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native Asian Native Hawaiian or Pacific Islander Other Prefer not to answer No response u have a disability? Yes
165 <10 <10 12 <10 <10 <10 0 19 16 Q79. Do yo <10	which race do you most identify? Please select all that apply. White Black or African American American Indian or Alaska Native Asian Native Hawaiian or Pacific Islander Other Prefer not to answer No response u have a disability? Yes No